{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:07:21Z","timestamp":1791425241466,"version":"4.3.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The United Kingdom\u2019s (UK) integration of Pre-exposure Prophylaxis (PrEP) into community pharmacies presents an alternative avenue for supporting Human Immunodeficiency Virus (HIV) prevention. Despite its effectiveness, PrEP's accessibility remains hindered by various barriers within community settings. The aim of this study was\u00a0to explore the perspectives of pharmacy team members regarding the barriers and facilitators to the routine provision of PrEP in community pharmacies in the UK, as well as any recommendations for mitigating these challenges.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Exploratory mixed-method cross-sectional\u00a0study utilising an online survey and semi-structured interviews with community pharmacists and non-pharmacist team members across the North Thames area of London, England.<\/jats:p>\n            <jats:p>A convenience sample of 110 pharmacy team members participated in the study, including both pharmacists and non-pharmacists. Two pharmacy technicians and eight pharmacists took part in semi-structured interviews.<\/jats:p>\n            <jats:p>Data collection involved a cross-sectional online survey and semi-structured interviews. The survey collected data such as demographic characteristics, knowledge, and attitudes towards PrEP provision, while interviews explored in-depth perceptions, experiences and recommendations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A significant proportion of respondents expressed a lack of confidence and knowledge regarding PrEP, with training identified as a critical need for facilitating PrEP provision. Additionally, the study highlighted the potential of community pharmacies to increase accessibility of PrEP due to their geographical reach and the trust placed in pharmacists.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The study demonstrates an interest from community pharmacies in London in providing a commissioned PrEP supply service. However, this would need to be in conjunction with training programmes and public health campaigns to equip community pharmacies for effective PrEP provision. Enhancing pharmacists' competencies and raising public awareness could significantly support the current HIV prevention strategies in the UK.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12913-025-12336-1","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T14:32:00Z","timestamp":1740493920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Investigating facilitators and barriers to the routine provision of HIV PrEP in community pharmacies in London"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5662-7943","authenticated-orcid":false,"given":"Marsha","family":"Alter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5930-1292","authenticated-orcid":false,"given":"Shivali","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-5092","authenticated-orcid":false,"given":"Aos","family":"Alaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6996-8915","authenticated-orcid":false,"given":"Manisha","family":"Karki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9922-9125","authenticated-orcid":false,"given":"Eva","family":"Riboli-Sasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8772-4938","authenticated-orcid":false,"given":"Austen","family":"El-Osta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"12336_CR1","unstructured":"Organization, W.H. HIV\/ AIDS - Pre-exposure prophylaxis. Available from: https:\/\/www.who.int\/hiv\/topics\/prep\/en\/."},{"key":"12336_CR2","unstructured":"HIV.gov. Pre-Exposure Prophylaxis. 2020; Available from: https:\/\/www.hiv.gov\/hiv-basics\/hiv-prevention\/using-hiv-medication-to-reduce-risk\/pre-exposure-prophylaxis."},{"issue":"151","key":"12336_CR3","doi-asserted-by":"publisher","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","volume":"4","author":"PL Anderson","year":"2012","unstructured":"Anderson PL, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125.","journal-title":"Sci Transl Med"},{"issue":"5","key":"12336_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410.","journal-title":"N Engl J Med"},{"key":"12336_CR5","unstructured":"Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users. MMWR Morb Mortal Wkly Rep, 2013. 62(23): p 463\u20135."},{"key":"12336_CR6","unstructured":"Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach, 2nd ed. World Health Organization; Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241549684."},{"key":"12336_CR7","unstructured":"Global data shows increasing prep use and widespread adoption of WHO prep recommendations. World Health Organization; Available from: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/global-data-shows-increasing-prep-use-and-widespread-adoption-of-who-prep-recommendations."},{"key":"12336_CR8","unstructured":"NHS England, Clinical Commissioning Policy: Treatment as Prevention (TasP) in HIV infected adults. 2015."},{"issue":"10229","key":"12336_CR9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(20)30720-0","volume":"395","author":"T Kirby","year":"2020","unstructured":"Kirby T. PrEP finally approved on NHS in England. Lancet. 2020;395(10229):1025.","journal-title":"Lancet"},{"key":"12336_CR10","unstructured":"PrEPWatch. https:\/\/www.prepwatch.org\/data-by-country\/."},{"key":"12336_CR11","doi-asserted-by":"crossref","unstructured":"Todd, A., Copeland, A., Husband, A., Kasim, A., Bambra, C., Access all areas? an area-level analysis of accessibility to general practice and Community Pharmacy Services in England by urbanity and social, https:\/\/bmjopen.bmj.com\/content\/bmjopen\/5\/5\/e007328.full.pdf.","DOI":"10.1136\/bmjopen-2014-007328"},{"key":"12336_CR12","unstructured":"NHS England \u00bb Making Every Contact Count (MECC): Consensus statement ; Available from: https:\/\/www.england.nhs.uk\/publication\/making-every-contact-count-mecc-consensus-statement\/."},{"key":"12336_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/PPA.S30244","volume":"6","author":"P Saberi","year":"2012","unstructured":"Saberi P, et al. The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review. Patient Prefer Adherence. 2012;6:297\u2013322.","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"12336_CR14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/MLR.0b013e3181e57962","volume":"48","author":"MA Chisholm-Burns","year":"2010","unstructured":"Chisholm-Burns MA, et al. US pharmacists\u2019 effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010;48(10):923\u201333.","journal-title":"Med Care"},{"key":"12336_CR15","unstructured":"Ali Ahmed et al., Effect of pharmacist care on clinical outcomes among people living with HIV\/AIDS: A systematic review and meta-analysis Elsevier; 2021. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1551741121002783."},{"issue":"5","key":"12336_CR16","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1377\/hlthaff.27.5.1283","volume":"27","author":"M Thygeson","year":"2008","unstructured":"Thygeson M, et al. Use and costs of care in retail clinics versus traditional care sites. Health Aff (Millwood). 2008;27(5):1283\u201392.","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"12336_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11096-012-9709-0","volume":"34","author":"C Bruno","year":"2012","unstructured":"Bruno C, Saberi P. Pharmacists as providers of HIV pre-exposure prophylaxis. Int J Clin Pharm. 2012;34(6):803\u20136.","journal-title":"Int J Clin Pharm"},{"key":"12336_CR18","unstructured":"Sexual health Available from: https:\/\/new.haringey.gov.uk\/health-wellbeing\/health-services-support\/sexual-health."},{"key":"12336_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-2288-14-34","volume":"14","author":"JC Jakobsen","year":"2014","unstructured":"Jakobsen JC, et al. The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Med Res Methodol. 2014;14:34.","journal-title":"BMC Med Res Methodol"},{"key":"12336_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2288-14-120","volume":"14","author":"JC Jakobsen","year":"2014","unstructured":"Jakobsen JC, et al. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol. 2014;14:120.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"12336_CR21","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.2196\/jmir.6.3.e34","volume":"6","author":"G Eysenbach","year":"2004","unstructured":"Eysenbach G. Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res. 2004;6(3):e34\u2013e34.","journal-title":"J Med Internet Res"},{"key":"12336_CR22","doi-asserted-by":"publisher","first-page":"e074256","DOI":"10.1136\/bmj-2022-074256","volume":"381","author":"CH Saunders","year":"2023","unstructured":"Saunders CH, et al. (2023) Practical thematic analysis: a guide for multidisciplinary health services research teams engaging in qualitative analysis. BMJ. 2023;381:e074256.","journal-title":"BMJ"},{"key":"12336_CR23","unstructured":"Smith, S.E. and Tallentire, V.R. (2024) A new dawn for qualitative research in the BMJ, The BMJ. Available at: https:\/\/www.bmj.com\/content\/381\/bmj-2022-074256\/."},{"issue":"6","key":"12336_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P. Craig, J \u201ca 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"issue":"8","key":"12336_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/hiv.13492","volume":"24","author":"F Coukan","year":"2023","unstructured":"Coukan F, et al. Barriers and facilitators to HIV Pre-Exposure Prophylaxis (PrEP) in specialist sexual health services in the United Kingdom: a systematic review using the PrEP care continuum. HIV Med. 2023;24(8):893\u2013913.","journal-title":"HIV Med"},{"issue":"7","key":"12336_CR26","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S2352-3018(23)00080-2","volume":"10","author":"I Whelan","year":"2023","unstructured":"Whelan I, et al. Barriers and facilitators to HIV pre-exposure prophylaxis for cisgender and transgender women in the UK. Lancet HIV. 2023;10(7):e472\u201381.","journal-title":"Lancet HIV"},{"issue":"11","key":"12336_CR27","doi-asserted-by":"publisher","first-page":"e005717","DOI":"10.1136\/bmjopen-2014-005717","volume":"4","author":"I Young","year":"2014","unstructured":"Young I, Flowers P, McDaid LM. Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland. BMJ Open. 2014;4(11):e005717.","journal-title":"BMJ Open"},{"issue":"3","key":"12336_CR28","doi-asserted-by":"publisher","first-page":"e26232","DOI":"10.1002\/jia2.26232","volume":"27","author":"C Harrison","year":"2024","unstructured":"Harrison C, Family H, Kesten J, Denford S, Scott A, Dawson S, et al. Facilitators and barriers to community pharmacy delivery: a scoping review. J Int AIDS Soc. 2024;27(3):e26232. https:\/\/doi.org\/10.1002\/jia2.26232.","journal-title":"J Int AIDS Soc"},{"issue":"10","key":"12336_CR29","doi-asserted-by":"publisher","first-page":"e0292289","DOI":"10.1371\/journal.pone.0292289","volume":"18","author":"J MacDonald","year":"2023","unstructured":"MacDonald J, et al. Improving HIV pre-exposure prophylaxis (PrEP) adherence and retention in care: Process evaluation and recommendation development from a nationally implemented PrEP programme. PLoS ONE. 2023;18(10):e0292289.","journal-title":"PLoS ONE"},{"key":"12336_CR30","unstructured":"Robertson, J., Roadmap exploring PrEP access through pharmacies to be published by year end, in The Pharmacist, 2023."},{"issue":"6","key":"12336_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.sapharm.2014.12.006","volume":"11","author":"EM Seston","year":"2015","unstructured":"Seston EM, et al. Black and minority ethnic pharmacists\u2019 treatment in the UK: a systematic review. Res Social Adm Pharm. 2015;11(6):749\u201368.","journal-title":"Res Social Adm Pharm"},{"key":"12336_CR32","unstructured":"NHS England, Pharmacy Workforce Race Equality Standard report. 2023."},{"key":"12336_CR33","unstructured":"England PH., Pharmacy offer for Sexual Health, Reproductive Health and HIV GOV.UK; 2019 https:\/\/www.gov.uk\/government\/publications\/pharmacy-offer-for-sexual-health-reproductive-health-and-hiv."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12336-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T14:32:09Z","timestamp":1740493929000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12336-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12336"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12336-1","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent from all participants to participate were gained for this study.Ethical approval was gained from the Imperial College Research Ethics Committee (ICREC) for the study \u201cInvestigating facilitators and barriers to the routine provision of HIV PrEP in community pharmacies in London\u201d (ICREC #21IC6934).The study adhered to the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors consent to publication.Consent to publish data involving identifying images or other personal or clinical details of participants which could compromise anonymity is not applicable to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"312"}}